Learn about our work and hear what our clients have to say.
As a CCRM subsidiary, OmniaBio is building on an established foundation and reputation in manufacturing for cell and gene therapies, expanding on a knowledge base and legacy that has been built over a decade. Our teams have collaborated as a CDMO partner working with the following organizations or on the following projects:
Nkarta – in a project that achieved cost-effective manufacturing, under tight timelines, as a CDMO partner for clinical-phase manufacturing of a natural killer cell product.
“We’ve found an ongoing partner” – Dr. Ralph Brandenberger, SVP Technical Operations, Nkarta
DiscGenics – in a collaboration that developed a novel process to enable efficient manufacturing of an allogeneic therapy.
“[The team] really helped us get to where we are today.” – Dr. Lara Ionescu Silverman, PhD, Senior Director, Research and Development, DiscGenics
Avectas – in a project to accelerate the translation of SOLUPORE™ into the clinic. Our teams developed a unique intracellular delivery platform to enable ex vivo cell-based therapies.
“OmniaBio’s culture and adaptive nature, flexibility and communication were excellent.” – Edel O’Toole, Senior Director Project & Vendor Management, Avectas
The Cystic Fibrosis (CF) Canada Program in Individualized Therapy (CFIT). Learn how our team collaborated with an academic lab at The Hospital for Sick Children to establish a bank of 100 patient-derived iPSC lines and isogenic controls.
“The team has shared valuable expertise with our team, benefiting the project overall.”
– Dr. Christine Bear, The Hospital for Sick Children
Process Development for Scaled-Up hESC/hiPSC Manufacturing
Read about an optimized 14-day manufacturing workflow that produces >1010 cells.
Manufacturing of Pluripotent Stem Cell-Derived Cardiomyocytes for Pre-Clinical Animal Studies
Find out how we worked with a member of the local academic community to translate a cell therapy protocol from bench-scale to bioreactor.
Animal Component Free (ACF) Media Development for Cell Therapies
Understand how ACF media can achieve comparable performance to serum-containing media.